The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers sho
Similar Posts
BAKKAVOR USA Issues Allergy Alert for 16-Ounce Meal Simple Red Lentil Dal Soup Due to Undeclared Milk
Charlotte, NC (December 9, 2025) – Bakkavor USA of Charlotte, North Carolina, is initiating a recall of 16-ounce Meal Simple brand Red Lentil Dal Soup, BEST BY 1/11/2026 as it contains undeclared milk. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threateniGuidance Snapshot Pilot
Guidance Snapshots are a communication tool that provide highlights from the document using visuals and plain language. This pilot program is intended to increase awareness for FDA guidance documents to support the efficient application of the documents’ recommendations.Advancing Clinical Trial Participation for the LGBTQIA+ Community
Representatives of the FDA were fortunate to attend a community discussion on advancing clinical trial diversity for sexual and gender minority communities to help improve the generalizability of trial results across the entire population of patients who may use medical products.African Food on Wheels Inc. Recalls Oven Dried Fish (Scomberomorus Cavalla) Because of Possible Health Risk
African Food on Wheels Inc. of Bronx, NY is recalling 28 boxes of Product, because it is a dried, un-eviscerated (internal organs not removed) fish greater than 5 inches and length and has the potential to be contaminated with Clostridium botulinum, a bacterium which can cause life-threatening illneE21 Inclusion of Pregnant and Breastfeeding Women in Clinical Trials
The objective of this guideline is to provide recommendations for the appropriate inclusion and/or retention of pregnant and/or breastfeeding women in clinical trials and facilitate the generation of robust clinical data that allow for evidence-based decision making on the safe and effective use ofCommissioner’s National Priority Voucher (CNPV) Pilot Program Submission
This new pilot program is designed to accelerate the development and review of certain drugs and biological products that are aligned with U.S. national health priorities and to enhance the health interests of Americans.